145 related articles for article (PubMed ID: 21207415)
21. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
[TBL] [Abstract][Full Text] [Related]
22. Anti-tumor and anti-angiogenic effects of Fucoidan on prostate cancer: possible JAK-STAT3 pathway.
Rui X; Pan HF; Shao SL; Xu XM
BMC Complement Altern Med; 2017 Aug; 17(1):378. PubMed ID: 28764703
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of tumor angiogenesis by targeting endothelial surface ATP synthase with sangivamycin.
Komi Y; Ohno O; Suzuki Y; Shimamura M; Shimokado K; Umezawa K; Kojima S
Jpn J Clin Oncol; 2007 Nov; 37(11):867-73. PubMed ID: 17956898
[TBL] [Abstract][Full Text] [Related]
24. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
25. Pentoxifylline inhibits melanoma tumor growth and angiogenesis by targeting STAT3 signaling pathway.
Kamran MZ; Gude RP
Biomed Pharmacother; 2013 Jun; 67(5):399-405. PubMed ID: 23639230
[TBL] [Abstract][Full Text] [Related]
26. Indirubin suppresses ovarian cancer cell viabilities through the STAT3 signaling pathway.
Chen L; Wang J; Wu J; Zheng Q; Hu J
Drug Des Devel Ther; 2018; 12():3335-3342. PubMed ID: 30323565
[TBL] [Abstract][Full Text] [Related]
27. Indirubin-3'-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MAPK.
Zhen Y; Sørensen V; Jin Y; Suo Z; Wiedłocha A
Oncogene; 2007 Sep; 26(44):6372-85. PubMed ID: 17533378
[TBL] [Abstract][Full Text] [Related]
28. STAT3-targeting RNA interference inhibits pancreatic cancer angiogenesis in vitro and in vivo.
Huang C; Jiang T; Zhu L; Liu J; Cao J; Huang KJ; Qiu ZJ
Int J Oncol; 2011 Jun; 38(6):1637-44. PubMed ID: 21479358
[TBL] [Abstract][Full Text] [Related]
29. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
30. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
Wang D; Tang F; Wang S; Jiang Z; Zhang L
Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
[TBL] [Abstract][Full Text] [Related]
31. A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo.
Rastelli L; Valentino ML; Minderman MC; Landin J; Malyankar UM; Lescoe MK; Kitson R; Brunson K; Souan L; Forenza S; Goldfarb RH; Rabbani SA
Int J Oncol; 2011 Aug; 39(2):401-8. PubMed ID: 21567086
[TBL] [Abstract][Full Text] [Related]
32. Indirubin-3'-monoxime, a derivative of a chinese antileukemia medicine, inhibits angiogenesis.
Kim JK; Shin EK; Kang YH; Park JH
J Cell Biochem; 2011 May; 112(5):1384-91. PubMed ID: 21337385
[TBL] [Abstract][Full Text] [Related]
33. Ursolic acid inhibits colorectal cancer angiogenesis through suppression of multiple signaling pathways.
Lin J; Chen Y; Wei L; Hong Z; Sferra TJ; Peng J
Int J Oncol; 2013 Nov; 43(5):1666-74. PubMed ID: 24042330
[TBL] [Abstract][Full Text] [Related]
34. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
LaMontagne KR; Butler J; Borowski VB; Fuentes-Pesquera AR; Blevitt JM; Huang S; Li R; Connolly PJ; Greenberger LM
Angiogenesis; 2009; 12(3):287-96. PubMed ID: 19544081
[TBL] [Abstract][Full Text] [Related]
35. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells.
Nam S; Buettner R; Turkson J; Kim D; Cheng JQ; Muehlbeyer S; Hippe F; Vatter S; Merz KH; Eisenbrand G; Jove R
Proc Natl Acad Sci U S A; 2005 Apr; 102(17):5998-6003. PubMed ID: 15837920
[TBL] [Abstract][Full Text] [Related]
36. 6-Bromoindirubin-3'-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells.
Liu L; Nam S; Tian Y; Yang F; Wu J; Wang Y; Scuto A; Polychronopoulos P; Magiatis P; Skaltsounis L; Jove R
Cancer Res; 2011 Jun; 71(11):3972-9. PubMed ID: 21610112
[TBL] [Abstract][Full Text] [Related]
37. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling.
Yi T; Yi Z; Cho SG; Luo J; Pandey MK; Aggarwal BB; Liu M
Cancer Res; 2008 Mar; 68(6):1843-50. PubMed ID: 18339865
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of angiogenesis: a novel antitumor mechanism of the herbal compound arctigenin.
Gu Y; Scheuer C; Feng D; Menger MD; Laschke MW
Anticancer Drugs; 2013 Sep; 24(8):781-91. PubMed ID: 23744558
[TBL] [Abstract][Full Text] [Related]
39. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
40. The JAK/STAT3 signalling pathway regulated angiogenesis in an endothelial cell/adipose-derived stromal cell co-culture, 3D gel model.
Xue C; Xie J; Zhao D; Lin S; Zhou T; Shi S; Shao X; Lin Y; Zhu B; Cai X
Cell Prolif; 2017 Feb; 50(1):. PubMed ID: 27667148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
